In our study, we observed that one patient with endometrial cancer harboring a deleterious PTEN variant and one patient with metastatic basal cell carcinoma (skin cancer) carrying a deleterious variant of RAD51C responded to olaparib treatment. The gene discussed is PTEN; the disease is endometrial cancer.